Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,322 | 1,432 | 1,711 | 2,033 | 2,481 |
| Receivables | 1 | 0 | 1 | 3 | 3 |
| TOTAL | $1,596 | $1,899 | $1,899 | $2,279 | $2,712 |
| Non-Current Assets | |||||
| PPE Net | 19 | 21 | 23 | 26 | 29 |
| Other Non-Current Assets | 106 | 117 | 128 | 139 | 15 |
| TOTAL | $125 | $138 | $151 | $165 | $44 |
| Total Assets | $1,720 | $2,037 | $2,051 | $2,443 | $2,756 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | 710 | 200 | 200 |
| Accounts payable and accrued liabilities | 1,908 | 2,094 | 1,941 | 1,894 | 1,598 |
| Accrued Expenses | 111 | 72 | 127 | 82 | 46 |
| TOTAL | $8,660 | $8,192 | $8,824 | $8,494 | $7,825 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 1,306 | 1,511 | 1,676 | 1,991 | 2,312 |
| Other Non-Current Liabilities | 62 | 73 | 85 | 96 | 0 |
| TOTAL | $62 | $73 | $85 | $96 | $N/A |
| Total Liabilities | $8,722 | $8,266 | $8,909 | $8,591 | $7,825 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 419,497 | 419,497 | 419,547 | 419,497 | 419,447 |
| Common Shares | 420 | 420 | 420 | 419 | 419 |
| Retained earnings | -250,416 | -249,589 | -248,856 | -248,143 | -247,065 |
| Other shareholders' equity | -13 | -26 | -24 | -14 | -14 |
| TOTAL | $-7,002 | $-6,229 | $-6,859 | $-6,147 | $-5,069 |
| Total Liabilities And Equity | $1,720 | $2,037 | $2,050 | $2,443 | $2,756 |